Login
$TARS
$78.16 -$2.12 (2.64%) Live

$TARS SEC Filings

Filed On Filing
13 Nov 2026 144
05 Nov 2026 Form 4: Clase Neera, Chief Commercial Officer

Granted 10,587 Stock Option (right to buy) · Granted 6,678 Restricted Stock Units

05 Nov 2026 Form 3: Clase Neera, Chief Commercial Officer

Holds 14,800 shares of Common Stock

05 Nov 2026 SCHEDULE 13G
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year

13 Oct 2026 S-3ASR
13 Oct 2026 S-3ASR
13 Oct 2026 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma condensed combined financial information combines the historical financial position and results of operations of Tarsus Pharmaceuticals, Inc., a Delaware corporation (“Tarsus”), and Alkeus Pharmaceutical...

17 Sep 2026 Form 4: Pyott David E I, Director

Received 201 shares by exercise or conversion

17 Sep 2026 Form 4: Yarno Wendy L, Director

Received 302 shares by exercise or conversion

17 Sep 2026 Form 4: Link William J Phd, Director

Received 201 shares by exercise or conversion · Sold 12,500 shares ($980K)

15 Sep 2026 144
10 Sep 2026 8-K: Completion of Acquisition or Disposition of Assets; Other Events

Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMIS...

09 Sep 2026 Form 4: Azamian Bobak R., Director

Sold 10,000 shares ($906K)

09 Sep 2026 Form 4: Lin Elizabeth Yeu, Chief Medical Officer

Sold 13,953 shares ($1.22M)

09 Sep 2026 Form 4: Neervannan Seshadri, Chief Operating Officer

Sold 4,564 shares ($388K)

04 Sep 2026 144
04 Sep 2026 144
04 Sep 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support